Predict your next investment

AuriGen Medical company logo
HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
aurigenmedical.com

See what CB Insights has to offer

Stage

Incubator/Accelerator | Alive

Total Raised

$2.9M

About AuriGen Medical

AuriGen Medical is a structural heart and EP company, developing an entirely trans-septal implant to treat both the stroke and arrhythmia risk associated with persistent atrial fibrillation.

AuriGen Medical Headquarter Location

Dublin Road

Galway, H91 DCH9,

Ireland

+353 872431323

Latest AuriGen Medical News

NUI Galway researchers awarded €10.3 million

Jul 7, 2020

The Disruptive Technologies Innovation Fund was established under Project Ireland 2040. NUI Galway researchers and company partners have been awarded over €10.3 million in the Disruptive Technologies Innovation Fund (DTIF). The fund was established under Project Ireland 2040 and is run by the Department of Business, Enterprise and Innovation with administrative support from Enterprise Ireland. Two of the funded projects will see teams at NUI Galway partnering with AuriGen Medical, a NUI Galway spin-out company specialising in electrophysiology and structural heart, dedicated to transforming the management of persistent atrial fibrillation. A third DTIF supported project will see the collaboration between teams at the NUI Galway Centre for Cell Manufacturing (CCMI) and ONK Therapeutics Ltd. ONK Therapeutics is also a NUI Galway spin out who are a clinically focused company and have developed a disease-specific cell product approach to treat cancers. “Such collaboration between a NUI Galway spin-out company and its high quality academic research teams is exactly what we look for in this fund” The project will be co-led by professors Martin O’Halloran, Adnan Elahi and Leo Quinlan, which will allow the Translational Medical Device Lab (TMD-Lab) to continue and grow its research collaboration with AuriGen Medical. It will support the development of a novel medical device for the treatment of atrial fibrillation and ultimately stroke. The project will also explore the fundamental science of electroporation on both a cellular and tissue level, while also translating this basic science into a refined and optimised patient treatment. The second project in collaboration with AuriGen Medical will support the development of sensors for monitoring the treatment of atrial fibrillation, and long-term patient management to prevent stroke and other heart diseases. “We are focussed on developing game-changing technologies with the potential to disrupt markets” The sensors and monitoring system will aid in delivering effective treatment and allow for data-driven disease management in associated long-term heart conditions. Led by Professor William Wyns and Dr Atif Shahzad from the Smart Sensors Laboratory, the team will extend its existing expertise and knowledge in the area of novel biosensors and AI driven connected health solutions to deliver on this multifaceted technology challenge. Enterprise Ireland distruptive technologies department manager, Imelda Lambkin, extended congratulations to Professor Wyns and Dr Shahzad and AuriGen Medical, commenting: “I congratulate AuriGen Medical and their research partners in the Translational Medical Device and Smart Sensors Labs at NUI Galway on their success in the Disruptive Technologies Innovation Fund. “Such collaboration between a NUI Galway spin-out company and its high quality academic research teams is exactly what we look for in this fund, where we are focussed on developing game-changing technologies with the potential to disrupt markets. We look forward to supporting the team in achieving their global ambition of bringing novel cardiac implants to fruition.” Professor Timothy O’Brien, dean of the College of Medicine Nursing and Health Sciences at NUI Galway and consultant endocrinologist at Saolta University Healthcare Group acknowledges the key role of collaborations between NUI Galway and industry for medical advancement. “Funding, like the Disruptive Technology Innovation Fund, makes it possible for innovative academic teams to partner with local indigenous industry to develop essential medical innovations. It provides the supportive environment for collaborative breakthroughs,” he added. Published: 7 July, 2020

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AuriGen Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AuriGen Medical is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,753 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Bioelectronics

813 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.